carbonic acid;N,N-diethylethanamine | 15715-57-8

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: carbonic acid;N,N-diethylethanamine
• CAS: 15715-57-8
• 化学式: C13H32N2O3
• 分子量: 264.4
• InChiKey: STNNHWPJRRODGI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.92
• 重原子数：
  18
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  64
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  Tert-butyl (1-{(3E)-4-[4-amino-3-(3-methoxy-4-{[(1-methyl-1H-indol-2-yl)carbonyl]amino}phenyl)thieno[3,2-c]pyridin-7-yl]but-3-enyl}piperidin-4-yl)methylcarbamate 、 carbonic acid;N,N-diethylethanamine 以 二氯甲烷 为溶剂， 反应 16.0h， 以to give 0.02 g (29%) of the title compound的产率得到N-[4-(4-amino-7-{(1E)-4-[4-(aminomethyl)piperidin-1-yl]but-1-enyl}thieno[3,2-c]pyridin-3-yl)-2-methoxyphenyl]-1-methyl-1H-indole-2-carboxamide
  参考文献：
  名称：

  THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS

  摘要：

  具有化学式的化合物对于抑制蛋白质酪氨酸激酶具有用处。本发明还公开了制备该化合物的方法、含有该化合物的组合物以及使用该化合物的治疗方法。

  公开号：

  US20070155776A1
• 作为试剂：
  描述：

  (5R)-3-[4-(6-{(5S)-5-[(4R)-2,2-dimethyl-1,3-dioxolan-4-yl]-4,5-dihydroisoxazol-3-yl}pyridin-3-yl)-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-yhnethyl)-1,3-oxazolidin-2-one 、 盐酸 、 、 carbonic acid;N,N-diethylethanamine 在 乙腈 、 ice 、 carbonic acid;N,N-diethylethanamine 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 为溶剂， 反应 2.5h， 以to give the title product (0.072 g, 34.8% yield) as a white solid的产率得到(5R)-3-[4-(6-{(5S)-5-[(1R)-1,2-dihydroxyethyl]-4,5-dihydroisoxazol-3-yl}pyridin-3-yl)-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3,-oxazolidin-2-one
  参考文献：
  名称：

  Oxazolidinone and/or isoxazoline derivatives as antibacterial agents

  摘要：

  化合物的公式（I），或其药学上可接受的盐，或其体内水解酯的公式（I），其中在（I）中，C例如是公式（D），公式（E），公式（H），其中A和B分别选自（i）公式（J）和（ii）公式（K），m为1或2；R2b和R6b，R2a和R6a，R3a和R5a，例如选自H，F，OMe和Me；R2b'和R6b'，R2a'和R6a'，R3a'，R5a'例如选自H，OMe和Me；R1a例如是可选取代的（1-10C）烷基；R1b例如选自—NR5C（═W）R4，公式（a），或公式（b），其中HET-1例如是异恶唑基，HET-2例如是三唑基或四唑基。还描述了制备公式（I）化合物的方法，含有它们的组合物以及它们作为抗菌剂的用途。

  公开号：

  US20060116400A1

文献信息

• [EN] 6-1H-IMIDAZO-QUINAZOLINE AND QUINOLINES DERIVATIVES, NEW MAO INHIBITORS AND IMIDAZOLINE RECEPTOR LIGANDS<br/>[FR] DÉRIVÉS DE 6-1H-IMIDAZO-QUINAZOLINE ET QUINOLÉINES, NOUVEAUX INHIBITEURS DE MAO ET LIGANDS DES RÉCEPTEURS D'IMIDAZOLINES
  申请人：ROTTAPHARM SPA

  公开号：WO2009152868A1

  公开（公告）日：2009-12-23

  The present invention is directed to 6-(1H-imidazo-1-yl)-2-aryl and 2-heteroaryl quinazoline and quinolines derivatives, compounds of formula (I), their pharmaceutical acceptable salts and solvates and corresponding pharmaceutical compositions, that acts as Monoamine Oxidase (MAO) inhibitors and Imidazoline Receptor ligands: wherein: X is independently selected from -CH group or a nitrogen atom (-N), W is independently selected from an aryl group, an heteroaryl group, or a benzocondensed heteroaryl group such as 1,3-benzodioxole, benzofuran, 2,3-dihydrobenzofuran, benzothiophene, 2,3-dihydrobenzothiophene, indole, 2,3-dihydroindole, benzimidazole, benzoxazole, benzothiazole, 2H-3,4-dihydrobenzopyran, [l,4]-benzodioxine, 2,3-dihydro-[1,4]-benzodioxine (1,4-benzodioxan). R1 is independently selected from hydrogen (-H), C1-C4alkyl, hydroxymethyl (-CH2OH), aminomethyl (-CH2NH2), alkylaminomethyl [CH2NH(R2)], or di-alkylaminomethyl [CH2N(R2)2], trifiuoromethyl (-CF3). Compounds of formula (I) elicited a pharmacological profile suitable for the clinical treatment of depression and related disorders, Parkinson disease, drug abuse, and morphine tolerance and dependence.

  本发明涉及6-(1H-咪唑-1-基)-2-芳基和2-杂芳基喹唑啉和喹啉衍生物，这些衍生物的化学式为(I)，以及它们的药用盐和溶剂化物以及相应的药物组合物，作为单胺氧化酶（MAO）抑制剂和咪唑啉受体配体：其中：X独立地选自-CH基团或氮原子(-N)，W独立地选自芳基团、杂芳基团或如1,3-苯并二氧杂环戊烷、苯并呋喃、2,3-二氢苯并呋喃、苯并噻吩、2,3-二氢苯并噻吩、吲哚、2,3-二氢吲哚、苯并咪唑、苯并噁唑、苯并噻唑、2H-3,4-二氢苯并吡喃、[1,4]-苯并二氧杂环戊烷、2,3-二氢-[1,4]-苯并二氧杂环戊烷(1,4-苯并二氧杂环戊烷)。R1独立地选自氢(-H)、C1-C4烷基、羟甲基(-CH2OH)、氨基甲基(-CH2NH2)、烷基氨甲基[CH2NH(R2)]或二烷基氨甲基[CH2N(R2)2]、三氟甲基(-CF3)。化学式(I)的化合物展现出适合于临床治疗抑郁症和相关障碍、帕金森病、药物滥用以及吗啡耐受性和依赖性的药理特性。
• [EN] FLUORESCENT BISPHOSPHONATE ANALOGS<br/>[FR] ANALOGUES DE BISPHOSPHONATES FLUORESCENTS
  申请人：UNIV SOUTHERN CALIFORNIA

  公开号：WO2016161407A1

  公开（公告）日：2016-10-06

  Fluorescent probes based on N-heterocyclic bisphosphonates or their phosphonocarboxylate analogues are provided. The probes have variable spectroscopic properties, bone mineral binding affinities, and pharmacological activities. Methods for preparing the probes include the use of two complementary linking strategies, one involving an amino group and the other involving a chloride group as a precursor to an amino group. In other versions, bifunctional N-heterocyclic bisphosphonates are provided having an amino group and an azido group as linking moieties. In some versions, the linking chemistry allows attachment of a wide selection of fluorescent dyes in the visible to near-infrared range to any of three clinically important heterocyclic bisphosphonates.

  基于N-杂环双膦酸盐或其膦酸盐类似物的荧光探针已提供。这些探针具有可变的光谱特性、骨矿物结合亲和力和药理活性。制备这些探针的方法包括使用两种互补的连接策略，一种涉及氨基团，另一种涉及氯化物作为氨基团的前体。在其他版本中，提供了具有氨基团和偶氮基团作为连接基团的双功能N-杂环双膦酸盐。在某些版本中，连接化学允许将广泛选择的荧光染料附着在可见光到近红外范围内的三种临床重要的杂环双膦酸盐中的任何一种上。
• Labeling reagents and labeled targets, target labeling processes and other processes for using same in nucleic acid determinations and analyses
  申请人：——

  公开号：US20030225247A1

  公开（公告）日：2003-12-04

  This invention provides for labeling reagents, labeled targets and processes for preparing labeling reagents. The labeling reagents can take the form of cyanine dyes, xanthene dyes, porphyrin dyes, coumarin dyes or composite dyes. These labeling reagents are useful for labeling probes or targets, including nucleic acids and proteins. These reagents can be usefully applied to protein and nucleic acid probe based assays. They are also applicable to real-time detection processes.

  这项发明提供了用于标记试剂、标记靶物和制备标记试剂的过程。这些标记试剂可以采用青霉素染料、黄色素染料、卟啉染料、香豆素染料或复合染料的形式。这些标记试剂对于标记探针或靶物（包括核酸和蛋白质）非常有用。这些试剂可以被有益地应用于基于蛋白质和核酸探针的分析。它们也适用于实时检测过程。
• Inhibitors of aminoglycoside 6'-N-acetyltransferases, compositions and uses thereof
  申请人：Auclair Karine

  公开号：US20060211634A1

  公开（公告）日：2006-09-21

  The present invention relates to inhibitors of aminoglycoside 6′-N-acetyltransferases of Formula I: R—X—Y-Z  Formula I wherein: R is selected from the group consisting of: R 1 is selected from the group consisting of OH and R 2 is selected from the group consisting of OH and R 3 is selected from the group consisting of NH 2 and OH; R 4 is selected from the group consisting of NH 2 and R 5 is selected from the group consisting of OMe, OEt OPr, and O-iPr; X is selected from the group consisting of NH and O; Y is selected from the group consisting of: R 6 is selected from the group consisting of OH, CH 3 , and OCH 3 ; n is an integer ranging from 1 to 10; and Z is selected from the group consisting of: and R 7 is selected from the group consisting of OH, OMe, OEt OPr, O-iPr, O-tBu and

  本发明涉及公式I的氨基糖苷6'-N-乙酰转移酶抑制剂：R—X—Y-Z 其中：R选自以下组成的群体：R1选自OH和R2选自OH和R3选自NH2和OH；R4选自NH2和R5选自OMe、OEt、OPr和O-iPr；X选自NH和O；Y选自以下组成的群体：R6选自OH、CH3和OCH3；n为1至10的整数；Z选自以下组成的群体：和R7选自OH、OMe、OEt、OPr、O-iPr、O-tBu。
• SYNTHESIS OF DRUG CONJUGATES VIA REACTION WITH EPOXIDE-CONTAINING LINKERS
  申请人：McKenna Charles E.

  公开号：US20080312440A1

  公开（公告）日：2008-12-18

  The present invention relates to drug derivatives and linkers. The invention specifically relates to compounds and methods of phosphonates and linkers, that are useful as carriers for imaging agents and useful in the treatment of various bone diseases.

  本发明涉及药物衍生物和连接剂。具体涉及磷酸酯和连接剂的化合物和方法，这些化合物和方法可用作成像剂的载体，并在治疗各种骨疾病中有用。